Antagonist antibody to NPR1, REGN-NPR17544 (baloncibart), increases blood pressure and plasma volume

Authors:

Abstract
Hypotension and hypovolemia cause morbidity across many clinical disorders, yet pharmacologic options are limited. REGN-NPR1 7544 (REGN7544/baloncibart), a first-in-class monoclonal antibody, allosterically antagonizes natriuretic peptide receptor 1 (NPR1), a membrane guanylyl cyclase activated by atrial natriuretic peptide (ANP) and brain natriuretic peptide to promote vasorelaxation and natriuresis. REGN-NPR1 7544 bound human and cynomolgus monkey NPR1 with nanomolar affinity, increased systolic blood pressure (SBP) in NPR1 Hu/Hu mice by 10–15 mmHg for up to 28 days, corrected severe hypotension in ANP-overexpressing mice, and inhibited ANP-induced mesenteric vessel relaxation. In monkeys, SBP increased by 15–20 mmHg, with biomarkers consistent with plasma volume expansion. In a randomized, placebo-controlled, phase 1 single-ascending-dose study in healthy adults (N = 80), doses ≥ 100 mg were generally well-tolerated, producing sustained 5–10 mmHg SBP increases and biomarker signals consistent with volume expansion. These data implicate tonic NPR1 signaling in human blood pressure and volume regulation, supporting REGN-NPR1 7544 as a candidate for hypotension and hypovolemia.

This publication has 32 references indexed in Scilit: